On September 3, 2019 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), reported that management will be participating in the following two upcoming conferences this month (Press release, Infinity Pharmaceuticals, SEP 3, 2019, View Source [SID1234539227]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 2019 Healthcare Conference: Adelene Perkins, Infinity’s Chief Executive Officer, will present at Wells Fargo Securities14th Annual Healthcare Conference on Wednesday, September 4, 2019, at 1:50 p.m. ET at the Westin Copley Place in Boston, MA. A live webcast of the presentation will be available on the Investors/Media section of Infinity’s website at www.infi.com and will be available for 30 days following the event.

Morgan Stanley 17th Annual Global Healthcare Conference: Infinity’s management team will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11, 2019, at the Grand Hyatt New York, New York.

On September 3, 2019 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, reported that the company will present at three conferences in New York in the first half of September 2019 (Press release, Oramed Pharmaceuticals, SEP 3, 2019, View Source [SID1234539226]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RHK Capital 4th Annual Disruptive Growth Conference
Date: September 4, 2019
Time: 2:00 p.m.
Location: 599 Lexington Avenue, New York, NY
Presenter: Estee Yaari, Director, Corporate Communications

H. C. Wainwright 21st Annual Global Investment Conference
Date: September 9, 2019
Time: 9:10 a.m.
Location: Lotte New York Palace Hotel, New York
Presenter: Nadav Kidron, CEO

The Future of Healthcare Panel Discussion
Date: September 12, 2019
Time: 6:00 p.m.
Location: SOSA NYC
Presenter: Nadav Kidron, CEO

On September 3, 2019 Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") reported that Company management will participate at the following upcoming investment conferences in September (Press release, Intech Pharmaceuticals, SEP 3, 2019, https://www.prnewswire.com/news-releases/intec-pharma-to-participate-in-september-investment-conferences-300910451.html [SID1234539225]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HC Wainwright 21st Annual Global Investment Conference
Date: September 8-10, 2019
Company Presentation: Monday, September 9, 2019 at 4:40 pm (Eastern time)

Location: Lotte New York Palace Hotel, New York City
Presenter: Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma
Format: Corporate presentation and One-on-One Investor Meetings

Ladenburg Thalmann 2019 Healthcare Conference
Date: September 24, 2019

Company Presentation: September 24, 2019 at 11:30 am (Eastern time)
Location: Sofitel, New York City
Presenter: Walt Linscott, Chief Business Officer
Format: Corporate presentation and One-on-One Investor Meetings

Both presentations will be webcast live and will be accessible through the Events section of Intec Pharma’s website at www.intecpharma.com, where they will also be archived for a period of time.

On September 3, 2019 CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S., and throughout the world, reported it will present at the 2019 H.C. Wainwright 21st Annual Global Investment Conference being held September 8-10, 2019 in New York, NY (Press release, CASI Pharmaceuticals, SEP 3, 2019, https://www.prnewswire.com/news-releases/casi-pharmaceuticals-inc-to-present-at-the-2019-hc-wainwright-21st-annual-global-investment-conference-300909977.html [SID1234539224]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 21st Annual Global Investment Conference
Date: Monday, September 9th
Time: 11:40 AM – 12:05 PM
Presenter: Dr. Wei-Wu He
Presentation Room: Holmes II (4th floor) Lotte New York Palace Hotel

A link to the presentation’s webcast as well as a copy of the of the presentation can found on the Company’s website www.casipharmaceuticals.com, on September 9, 2019.

On September 3, 2019 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC (Press release, ProMIS Neurosciences, SEP 3, 2019, https://www.prnewswire.com/news-releases/promis-neurosciences-to-present-at-hc-wainwright-investment-conference-300909802.html [SID1234539223]). The conference is being held September 8-10, 2019 at the New York Palace Hotel in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ProMIS’ Executive Chairman, Eugene Williams will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis) Tuesday, September 10th at 10:25 am ET. The audio webcast and slides of Mr. Williams’ presentation will be archived and available on ProMIS’ web site and through the following link View Source